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AbstrACt
Introduction Many medicines have adverse effects which 
are difficult to detect and frequently go unrecognised. 
Pharmacist monitoring of changes in signs and symptoms 
of these adverse effects, which we describe as medicine- 
induced deterioration, may reduce the risk of developing 
frailty. The aim of this trial is to determine the effectiveness 
of a 12- month pharmacist service compared with usual 
care in reducing medicine- induced deterioration, frailty 
and adverse reactions in older people living in aged- care 
facilities in Australia.
Methods and analysis The reducing medicine- induced 
deterioration and adverse reactions trial is a multicentre, 
open- label randomised controlled trial. Participants will 
be recruited from 39 facilities in South Australia and 
Tasmania. Residents will be included if they are using 
four or more medicines at the time of recruitment, or 
taking more than one medicine with anticholinergic or 
sedative properties. The intervention group will receive 
a pharmacist assessment which occurs every 8 weeks. 
The pharmacists will liaise with the participants’ general 
practitioners when medicine- induced deterioration is 
evident or adverse events are considered serious. The 
primary outcome is a reduction in medicine- induced 
deterioration from baseline to 6 and 12 months, as 
measured by change in frailty index. The secondary 
outcomes are changes in cognition scores, 24- hour 
movement behaviour, grip strength, weight, percentage 
robust, pre- frail and frail classification, rate of adverse 
medicine events, health- related quality of life and health 
resource use. The statistical analysis will use mixed- 
models adjusted for baseline to account for repeated 
outcome measures. A health economic evaluation will be 
conducted following trial completion using data collected 
during the trial.
Ethics and dissemination Ethics approvals have been 
obtained from the Human Research Ethics Committee 
of University of South Australia (ID:0000036440) and 
University of Tasmania (ID:H0017022). A copy of the final 
report will be provided to the Australian Government 
Department of Health.
trial registration number Australian and New Zealand 
Trials Registry ACTRN12618000766213.
IntroduCtIon
Multiple medicine use is common in older 
people living in aged- care facilities, with a 
2015 systematic review reporting that up to 
three- quarters of all residents take more than 
nine medications.1 The use of multiple medi-
cines places older people at increased risk 
of harm. Up to 30% of unplanned hospital 
admissions in the population 65 years and 
over are medication- related and the majority 
of these are preventable.2–5 Assessment of 
medication reviews demonstrates that harm 
is frequent in the aged- care sector, with one 
review of 500 persons finding that there were 
strengths and limitations of this study
 ► The proposed pharmacist service in aged- care facil-
ities is currently not available in any private or public 
setting in Australia.
 ► Use of validated tools such as the Montreal cognitive 
assessment, dynamometer and activity tracker will
allow pharmacists to actively detect deterioration in
residents’ condition.
 ► Excluding people with moderate or severe dementia
and people with significant existing frailty burden
mean that the proportion of residents who could be
involved in the trial is likely to be low.
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Figure 1 ReMInDAR trial flow chart. Study participants will 
be recruited from aged- care facilities and allocated in a 1:1 
ratio to receive either the sessional pharmacist visit or usual 
care. Study outcome measures will be collected by RA at 
baseline, 6 months and 12 months. RA, research assistant; 
ReMInDAR, reducing medicine- induced deterioration and 
adverse reactions.
on average three medication- related problems per person; 
16% were identified as problems related to risk of adverse 
reactions.6 In a second study in the Australian aged- care 
setting, pharmacists retrospectively assessed medication- 
related problems for 847 residential medication manage-
ment reviews (RMMRs).7 Overall, 98% of the residents 
had at least one medication- related problem identified by 
the pharmacist, with an average of three problems per 
person; an adverse medicine event was present among 
15% of residents.7 Adverse medicine events encompass 
adverse drug reactions as well as harm that results from 
medication errors or system failures associated with the 
manufacture, distribution or use of medicines.8
In addition to recognised adverse medicine events, 
many medicines often have what might be considered 
‘minor side effects’ which are difficult to detect and 
frequently unrecognised. These side effects, particularly 
if the cumulative effects build over time, may be misat-
tributed as geriatric syndromes, frailty or ‘changes due to 
aging’. We describe these cumulative effects as medicine- 
induced deterioration,9 which encompasses symptoms 
such as cognitive and functional impairment, the latter 
of which may be due to muscle weakness or neuropathy, 
sedation that reduces physical activity, or falls. Additional 
symptoms that can be medicine- induced include loss of 
appetite, changes in urinary function and bowel function, 
changes in respiration and changes in activity or sleep 
patterns. While these symptoms may occur independently 
of medicine use, many medicines have side effect profiles 
that may cause or contribute to these symptoms. Medicine- 
induced deterioration can be further exacerbated where 
medicines with differing indications but similar or over-
lapping side effect profiles are used concurrently.
Medicines can affect a range of physiological systems 
including cognitive and physical function, both of which 
are components of frailty.10 This may partially explain the 
reason why there is significant evidence demonstrating 
that medicine use is associated with frailty.11–13 Frailty is a 
risk factor for adverse events including falls, delirium and 
hospitalisation,14 and frail individuals have worse health 
outcomes than non- frail individuals.11 12 15 Theoretically 
reducing medicine- induced deterioration would there-
fore reduce the potential for people to develop frailty and 
thus reduce the potential for adverse medicine events. 
Emerging longitudinal evidence suggests that medicines 
may worsen frailty, with longitudinal evidence showing 
that the cumulative load of anticholinergic and sedative 
medicines is associated with increased risk of developing 
pre- frail states.16 Once frail, individuals are also more 
vulnerable to adverse drug reactions.17 An Irish study 
demonstrated that the odds of developing an adverse 
reaction in frail persons were double that of a non- frail 
person (29% compared with 17% respectively, OR 2.1 
(95% CI 1.5 to 3.0).17
We therefore hypothesise that pharmacist monitoring 
of residents’ signs and symptoms of medicine- induced 
deterioration, including changes in mobility, cognition 
and strength, can prevent deterioration and reduce the 
risk of frailty. By detecting the immediate and cumula-
tive influence of medicine use on cognitive and func-
tional ability, as well as nutrition, continence, sleep and 
other changes in health status, there is the potential for 
early detection of medicine- induced deterioration and 
thus prevention of adverse events. The aim of our trial 
is to determine the effectiveness and cost- effectiveness 
of a pharmacist intervention compared with usual care 
in reducing medicine- induced deterioration, frailty and 
adverse reactions in older people in residential aged- care 
facilities in Australia. The term residential aged- care facil-
ities is synonymous with nursing homes in the USA where 
care is provided 24 hours a day, 7 days a week to relatively 
frail older residents.
MEthods And AnAlysIs
study design and setting
The reducing medicine- induced deterioration and 
adverse reactions (ReMInDAR) trial is a multicentre, 
open- label, randomised controlled trial with residents 
allocated in a 1:1 ratio (figure 1). Randomisation will be 
stratified at the level of the individual and not at the level 
of the facility. A list of resident randomisation codes and 
unique resident identification numbers will be generated 
electronically for each aged- care facility.
A total of 354 residents will be recruited from 39 
participating residential aged- care facilities across South 
Australia and Tasmania in Australia. Recruitment and 
pharmacist intervention will be rolled out for each site 
between August 2018 and June 2020. The ‘intervention’ 
is a sessional pharmacist assessment which will occur 
every 8 weeks at each facility for 12 months. Residents 
randomised to the control group will receive usual care 
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Figure 2 Flow chart for sessional pharmacist visit which 
occurs every 8 weeks. Pharmacists will identify any 
medication changes that have occurred since the last visit, 
assess for medicine- induced deterioration and adverse 
events, interview the participants and care staff to identify 
any concerns and make recommendations to the GP where 
necessary. AE, adverse event; GP, general practitioner; 
MCSD, minimal clinically significant difference.
provided under the existing aged- care pharmacist service 
agreement including medication dispensing and RMMR.
recruitment
Study participants will be recruited from 39 aged- care 
facilities across two Australian states, South Australia and 
Tasmania in Australia. Recruitment materials in the form 
of flyers will be distributed in each residential aged- care 
facility. Information will be given to all potentially eligible 
residents informing them of the introduction of the phar-
macist service.
Prior to participant recruitment, general practitioners 
(GPs) providing services to the aged- care facilities will 
receive a letter introducing the ReMInDAR trial. If the 
participants are assigned into the intervention group, 
GPs caring for the participants will receive a follow- up 
letter informing them of their patients’ trial allocation, 
and pharmacists make contact with them as appropriate.
Eligibility criteria
Residents will be included if they are using four or more 
medicines at the time of recruitment, or are taking more 
than one medicine with anticholinergic or sedative prop-
erties. Residents will be excluded if they (i) have signifi-
cant existing frailty, defined as a score of 0.40 or above 
using the frailty index,15 (ii) have moderate or severe 
dementia, measured using the Psychogeriatric Assess-
ment Scales18 or similar tools, (iii) are receiving pallia-
tive care or respite care or (iv) are involved in another 
research project which affects their participation in this 
study.
randomisation
A list of resident randomisation codes and unique partic-
ipant identification numbers (PINs) will be generated 
electronically for each facility. As participants enrol, they 
will be assigned to a treatment arm and will be allocated a 
PIN based on the next randomised allocation. Due to the 
nature of the intervention (pharmacist service), it is not 
possible to conceal allocation during the study period.
The statistician responsible for the main outcome anal-
ysis will be provided the PIN only and will be blinded to 
the intervention arm allocation. No data on the number 
of services provided during the course of the study will be 
provided to the statistician who will maintain blinding of 
intervention arm allocation.
Intervention
The intervention group will receive a sessional pharma-
cist service which occurs every 8 weeks (figure 2). The 
8- weekly session is considered a feasible time frame for
a potential nationally implemented service. Analysis of
data from aged- care facilities showed an average of seven
medication changes per resident per year, thus approxi-
mately every 2 months. Australian evidence shows that the
majority of adverse events occur within the first 4 weeks of
starting a medicine.19
The service includes assessment for adverse medicine 
events and medicine- induced deterioration including 
assessment of cognition (using the Montreal cognitive 
assessment (MoCA)),20 24- hour movement behaviour 
including sleep (Activinsights Bands, Activinsights Ltd21 
fitted for 1 year), and hand grip strength (dynamometer, 
Jamar).
All reviews across the 12- month period will be conducted 
by the same pharmacist assigned to the specific site, except 
under special circumstances such as pharmacist moving 
interstate. During the visit, the pharmacists will review 
electronic and/or hard copy participant care records 
to identify any new illnesses or conditions present since 
the last assessment. The pharmacists will review the care 
record to identify any adverse events (eg, falls, delirium 
events, bowel or urinary changes, weight loss) or any signs 
or symptoms noted in the care record that could be indic-
ative of adverse events (eg, changes in nutritional status, 
pain). The pharmacists will document any adverse events 
detected by GPs, nurses and care staff, and detect addi-
tional adverse events based on their clinical judgement. 
The pharmacists will also access the medication chart to 
identify any medication changes that have occurred since 
the last visit. The pharmacist will discuss with the partic-
ipants and care staff to identify any concerns that they 
may have.
The pharmacists will compare the results for the 
24- hour movement behaviour, MoCA test, grip strength
and weight with the most recent previous assessment and
with baseline data to identify immediate and cumula-
tive changes in each category. Where medicine- induced
deterioration is detected in the intervention- group
participants and considered clinically significant, the
pharmacists will liaise with the participants’ GPs to discuss
the participants’ condition, provide recommendations
on medication- related problems, communicate recom-
mended actions to and follow- up with the GP and facility
staff. The pharmacists will reassess the participant at the
next sessional visit to determine if medicine- induced
deterioration or adverse events have resolved and docu-
ment this.
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usual care
Residents in the aged- care facilities are eligible to receive 
RMMRs,22 and where required as part of usual care 
during the study period, this will still occur for partici-
pants in both intervention and control group. The 
RMMR is a comprehensive medication review conducted 
by an accredited pharmacist following a referral from the 
resident’s GP.22 Accredited pharmacists are funded to 
conduct an RMMR every 12–24 months, or where there 
has been a significant change in the residents’ condition 
or medication regimen.23
No intervention, other than usual care, will be provided 
to participants in the control group.
Primary outcome
The primary outcome is the reduction in medication- 
induced deterioration from baseline to 6 and 12 months, 
as measured by change in the frailty index.15
The frailty index15 is a 39- item instrument covering 
the following four domains: physical, medical, psycho-
logical and social. Measures within the physical domain 
include ability to undertake the physical activities of daily 
living, while within the medical domain comorbidities 
are included. Within the psychological domain, measures 
of cognitive function are assessed. Because medicine- 
induced deterioration is not limited to a single event, 
but can occur in either the physical, medical or psycho-
logical domains (eg loss of physical function or poorer 
cognition), an outcome measure that captures multiple 
domains is required. For this reason, the frailty index, 
which captures relevant domains, is being used as a surro-
gate measure of medicine- induced deterioration.
The frailty index has been validated in the population 
recruited for the Australian Longitudinal Study of the 
Ageing, where it was shown to have good predictive ability 
for adverse events of falls and hospitalisations.15 24
secondary outcomes
The secondary outcomes are mentioned below.
Change in cognition scores
Changes in cognition will be assessed using the MoCA 
test.20 This is the same tool that will be used in the phar-
macist intervention, and which is validated for screening 
in mild cognitive impairment.25
Change in 24-hour movement behaviour
Changes in 24- hour movement behaviour will be assessed 
using the GENEActiv accelerometer, a research- grade 
activity tracker which has been validated in adults for 
physical activity26 and for sedentary behaviour.27 The 
GENEActiv will be initialised to collect unfiltered, triaxial 
acceleration data at a sampling rate of 80 Hz. Output data 
will include number of sedentary and active bouts, sleep 
and active time using previously established cut- points. 
The GENEActiv will be worn on the wrist by participants 
in both the intervention and control group for a 7- day 
period.
Change in grip strength
Grip strength will be measured using a handheld dyna-
mometer (Jamar). The measurement will be undertaken 
using the dominant hand. Three measurements will be 
taken and the maximum of the three scores will be used. 
Cut- off points for grip strength that are considered reflec-
tive of sarcopaenia are 27 kg for men; 16 kg for women.28
Change in weight
Data on the weight of participants will be extracted from 
the resident serial weight chart, which forms part of the 
resident care assessment record.
Percentage robust, pre-frail and frail
The proportion of participants who are frail, pre- frail or 
robust will be measured using the frailty phenotype.29 
The frailty phenotype comprises five criteria: uninten-
tional weight loss, low grip strength, self- rated exhaus-
tion, low walking time and low physical activity. In the 
frailty phenotype, individuals are classified as frail if they 
meet three or more of the five criteria, and pre- fail if they 
have one or two attributes. Individuals who meet none of 
the criteria are classified as robust.
Rate of adverse medicine events
The rate of adverse medicine events will be measured 
as a composite outcome of any of the following adverse 
events: falls (non- injurious and injurious including frac-
tures), delirium, faecal impaction and hospitalisation. 
The number of adverse medicine events will be reported 
per resident per year.
Change in health-related quality of life
Health- related quality of life will be assessed using the 
EQ- 5D. The EQ- 5D is a simple generic health- related 
quality of life measure which provides utility weights 
enabling cost- effectiveness analysis.30 The questionnaire 
contains five dimensions (mobility, self- care, usual activ-
ities, pain/discomfort, anxiety/depression) and a visual 
analogue scale (range 0 to 100) representing current 
health state.
Change in health resource use (and costs and net costs/savings 
associated with the intervention)
Data will be collected on intervention- associated resource 
use, such as pharmacist, doctor, nursing and care staff 
time, changes in medication and non- medication manage-
ment and resource use associated with any adverse events.
Follow-up
All participants will undertake follow- up assessments at 6 
and 12 months where the research assistant will collect 
data on the study outcome measures.
data collection and storage
Table 1 outlines the data that will be collected throughout 
the study period. Research assistants at the aged- care facil-
ities will be responsible for collecting data for all partici-
pants at baseline, 6 months and 12 months and for entry 
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Table 1 Assessment and pharmacist service schedule
Task
Screening and 
baseline
Pharmacist 
service 
(intervention 
group only)
Outcome 
measures
Pharmacist 
service 
(intervention 
group only)
Outcome 
measures
Timeline (month) 0 Every 8 weeks 6 Every 8 weeks 12
Assess eligibility to enter trial x
Demographics, medical history, resident care 
assessment record
x
Randomisation x
Frailty index x x x
EQ- 5D x x x
Health resource use x x x
Activity tracker—GENEActiv x x x
Weight x x x x x
MoCA x x x x x
Dynamometer x x x x x
Activity tracker—Activinsights (intervention 
group only)
x x x x x
Identification of medication change x x
Identification of adverse events x x x x
General practitioner report if high risk of 
deterioration
x x
Reassess participant if medicine- induced 
deterioration or adverse event has resolved
x x
Outcome measures and assessment tools.
Activinsights: Health professional grade activity tracker fitted throughout study duration (1 year); dynamometer: instrument to measure 
grip strength; EQ- 5D, 5- item questionnaire and a visual analogue scale to measure quality of life; frailty index, 39- item multidimensional 
questionnaire to assess frailty; GENEActiv: Research grade activity tracker fitted for one week at baseline, 6 and 12 months; MoCA: Montreal 
Cognitive Assessment, a 30- point assessment for multiple cognitive domains.
x denotes the task is conducted during the visit.
into a custom- built web- based data management infor-
mation system. The pharmacists will be responsible for 
collecting data on medicine changes, medicine- induced 
deterioration and adverse events during the sessional 
pharmacist visits. Data will be stored in secure settings 
at the Quality Use of Medicines and Pharmacy Research 
Centre, University of South Australia. All study data will 
be stored in a de- identified format.
source data documentation and monitoring
A member of the research team will check data entered 
by each research assistant to ensure accurate data entry. 
Data for the first 50 participants entered into the elec-
tronic case report forms will be cross- referenced to the 
original source information by two members of the 
research team. In addition, two members of the research 
team will perform on- going source data verification 
(10% random sample of participants’ data) and review 
to confirm that the source data (eg, progress notes, medi-
cation chart, outcome measures) entered by the research 
assistants into the electronic case report forms are accu-
rate, complete and verifiable from the source documents. 
Each audit trail entry will be time- stamped, including 
when discrepancy occurs and data in the electronic case 
report forms are created, modified or deleted.
The study statistician will conduct regular remote 
monitoring on the web- based database by applying valida-
tion and consistency rules, with regular data cleaning to 
ensure the integrity of the study data.
training
The research assistants will receive training on the protocol 
and procedures, administration of study measures and 
completion of the electronic case report forms. Standard 
operating procedure manuals will be supplied for the 
research assistants and pharmacists to ensure consistency 
in study operation.
Pharmacists who agree to provide intervention services 
under the trial will be provided a 3- hour training session 
prior to commencement of the service. These pharma-
cists have a range of community, hospital and medication 
review (accredited) backgrounds. The training related 
to the trial will cover identification of medicine- induced 
deterioration, use of the assessment tools (Activinsight 
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band, handgrip dynamometer, MoCA, Resident Care 
Assessment Record Form), data collection and interpre-
tation of data.
To provide further training to pharmacists in the 
assessments and to ensure the intervention is able to be 
integrated into existing work flows, the clinical research 
leader or experienced clinical pharmacists will provide 
the intervention pharmacists with on- site support during 
the first sessional visit. The on- site support also aims to 
ensure consistency in that the pharmacists can adhere to 
the study protocol and are able to use the standardised 
tools correctly. Additional on- site support and training 
sessions will be conducted where necessary. Pharmacists 
are only able to undertake independent intervention 
delivery once clinical research leader is confident in their 
capacity to implement intervention as planned. Regular 
pharmacist discussion groups (every 2 months) will be 
convened to verify effective use of the tools, to support 
interpretation of the data and algorithms, to provide 
mentoring and to discuss solutions to all identified 
problems.
Analysis plan
Sample size calculation
The sample size calculation is based on the primary 
outcome, the change in frailty over 12 months and uses 
data from the Australian Longitudinal Study of Ageing.31 
If the intervention is assumed to prevent medicine 
induced frailty of half a deficit, then the treatment effect 
is a change in the frailty index of 0.015 with a SD of 0.06.3
Assuming a correlation in the frailty index over 12 
months of 0.7, a sample size of 302 will provide 80% 
power with two- sided α=0.05 to detect a difference in 
the change in the frailty index over 12 months of half a 
deficit. Allowing for a loss to follow- up of 17% based on 
a study of 12- month death rates in Australian aged- care 
residents with mild to moderate frailty,32 the total sample 
size required is 354.
Quantitative analysis
The trial analysis will follow a pre- specified statistical 
analysis plan. Participants will be analysed according to 
the treatment they were randomised to receive using 
an intention- to- treat approach. Multiple imputation 
for missing data in the primary outcome only will be 
performed using a ‘Missing At Random’ assumption and 
the ‘de jure estimand’ approach of Carpenter et al.33
Analyses will use mixed- effects models to account for 
correlated measurements from the same individual over 
time. To test whether the outcomes differ between the 
intervention groups, models will include fixed effects 
for treatment group, time point and an interaction 
term between treatment group and time point. Treat-
ment effects will be reported separately at 6 and 12 
months post- randomisation and statistical significance 
will be assessed at the two- sided 0.05 level. Both unad-
justed and adjusted analyses will be performed, with the 
adjusted analyses including the stratification variables 
(aged- care facility and gender) as covariates. If adjusting 
for a covariate prevents models from converging (eg, 
from small facilities), the covariate will be excluded and 
this will be noted in the reporting. Continuous outcomes 
will also be adjusted for baseline values. Conclusions on 
group differences will be based on the adjusted analyses. 
Planned subgroup analyses of the primary outcome are 
gender, baseline frailty phenotype, use of sedative and 
anticholinergic medications.
For continuous outcomes, linear regression models 
will be used with no planned data transformations. For 
ordinal categorical outcomes, proportional odds models 
will be used. Poisson or negative- binomial regression 
models will be used for the count outcomes, as appro-
priate. If the mixed models fail to converge, generalised 
estimating equations will be used instead.
Health economic analysis
The primary economic analysis will be a trial- based cost 
comparison from the perspective of the Australian health-
care system (public and private funded healthcare costs). 
The primary economic outcome will be average change 
in total health resource expenditure (net costs/ savings), 
associated with the pharmacist intervention, per resident, 
over a 1- year time horizon. These costs will be collected 
during the trial.
The analysis will use participant data on an ‘intention 
to treat’ basis (ie, residents will be analysed according to 
the intervention group to which they were randomised). 
Pharmaceutical benefits scheme (PBS) and medicare 
benefits schedule (MBS) administrative claims data, as 
well as administrative claims data for hospital admissions 
will be linked to the clinical effectiveness data collection 
set and used to inform the economic evaluation.
A trial- based cost effectiveness analysis and a trial- based 
cost- utility analysis will be conducted, if a reduction in 
medicine- induced frailty is shown. These analyses will 
provide preliminary first- year estimates of (i) the average 
incremental cost per adverse medicine event avoided 
and (ii) the incremental healthcare cost per quality- 
adjusted life year gained in health- related quality of life, 
as measured within trial by the EQ- 5D score.
Governance
The study will be governed by the trial steering committee 
comprising representatives from all consortium organisa-
tions. This committee will review and agree to all study 
planning documents and monitor the progress of the 
study. A trial management plan will be the master plan-
ning document outlining all requirements for successful 
implementation and completion of the study. This will be 
supported by a communications management plan, data 
management plan, quality management plan and intel-
lectual property management plan. Standard operating 
procedures will be established to operationalise aspects of 
all plans. A risk register and intellectual property register 
will be maintained and reviewed regularly.
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Patient and public involvement
Throughout the ReMInDAR trial stakeholders will be 
engaged through a number of mechanisms. The two 
primary mechanisms include a stakeholder advisory 
group and a consumer reference group. Representatives 
from key healthcare professional organisations, including 
aged- care, medical and pharmacy organisations, will meet 
annually as a stakeholder advisory committee to provide 
advice and support to the study. The consumer reference 
group will be convened prior to the trial commencing 
and again during the study implementation. Subsequent 
meetings will occur bi- annually. Residents and carers will 
be engaged to provide a consumer perspective on the 
study activities.
The trial pharmacists and residential aged- care staff will 
be invited to participate in discussion groups to review 
the study activities and the fit of these activities into staff 
workflows. In addition, qualitative interviews will form 
part of the study evaluation to determine participant satis-
faction with the service.
‘Opt out’ approach and consent to link data
The study will adopt an ‘opt out approach’, as requested 
by the residential aged- care facilities. In compliance with 
the National Statement of Ethical Conduct in Human 
Research section 2.3.6, flyers will be put up at all partic-
ipating residential aged- care facilities at least 1 month 
prior to recruitment to inform the residents, family 
members and staff of the introduction of the pharmacist 
service. In addition, flyers will be provided to all potential 
residents. The flyer will explain the pharmacist service, 
information on what to do if the residents do not wish to 
participate and inform the residents that they can opt out 
at any time throughout the study period.
Our study will exclude persons with moderate or severe 
dementia, meaning that the eligible residents will have 
the capacity to decline participation if they wish to do 
so. Written consent will be obtained separately from resi-
dents to access their MBS, PBS and state hospital data 
through the respective data custodians.
Participants who have enrolled in the study can with-
draw from the study for any reason or without having to 
give a reason.
dIsCussIon
The proposed pharmacist service in aged- care facilities 
is currently not available in any private or public setting 
in Australia. It is expected that the proposed pharmacist 
service will reduce the occurrence of adverse medicine 
events through early detection of medication- induced 
deterioration. Early detection of medicine- induced 
deterioration and prevention of deterioration by recom-
mending changes to medicines have the potential to 
significantly reduce medication- related problems and 
hospital admissions in older people, leading to substantial 
cost- savings in the Australian healthcare system. A recent 
study highlighted the need for well- designed, unbiased 
randomised controlled trials to include data relating to 
clinical outcomes associated with medicines use and our 
trial addresses this need.34
The increasingly complex healthcare system and rapid 
evolution of digital health tools mean it is essential to 
recalibrate research priorities of medicine safety to inte-
grate consumer- based wearable technologies. In 2017, the 
Australian Digital Health Agency established a new Medi-
cines Safety Programme which aims to integrate digital 
health within the healthcare setting to improve medicine 
use and safety.35 The development of digital health tools 
and resources creates an opportunity to understand and 
monitor medication safety; however, very little has been 
published in this field, including research involving 
older people living in aged- care facilities. In our study, 
the research- grade activity tracker (GENEActiv), which is 
used as a study outcome measure, provides raw triaxial 
acceleration data which will enable us to investigate 
how physical activity, including posture and sedentary 
behaviour (sitting or lying down) changes over 1 year in 
older people. In addition, use of the health professional- 
grade activity tracker (Activinsights) fitted over 1 year 
in the intervention group will allow us to actively detect 
deterioration in physical activity as well as understand the 
effects of medicine changes on physical activity in older 
people.
The focus of the trial is to investigate the effect of a 
pharmacist service to prevent deterioration caused by 
medicines. Studies have shown that medicine changes 
such as anticholinergic cessation do not improve cogni-
tive function in people who have dementia.36 37 There-
fore, we will exclude residents with moderate or severe 
dementia because we needed residents whose cognitive 
function is likely to change or deteriorate due to medi-
cine use. In addition, residents with significant existing 
frailty burden, defined as frailty index score ≥0.40, will 
be excluded because frailty index appears to reach a 
plateau by 0.5,38 meaning medicine changes affecting 
frailty may be harder to detect in residents who have 
a frailty index above 0.40. The exclusion criteria mean 
that the proportion of residents who could be involved 
is likely to be low because more than 50% of residents 
living in aged- care facilities in Australia have dementia39 
and between 50% and 90% of aged- care residents are 
frail.40
Continuous engagement with our stakeholder advisory 
group and consumer reference group will mean that 
the intervention is more likely to be acceptable to their 
needs and thus accepted into routine clinical patient care 
by healthcare professionals and consumers. It is antici-
pated that the pharmacist service will result in residents 
having less deterioration in physical and cognitive func-
tion, lower frailty burden and experiencing fewer adverse 
medicine events. If successful, the pharmacist service 
tested may provide a platform for a new standard of care 
which is likely to be easily integrated into existing prac-
tice, and which is readily accessible to residents in aged- 
care settings.
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Open access 
Ethics and dissemination
The study will be conducted in accordance with princi-
ples of the World Medical Association Declaration of 
Helsinki41 and the Australian National Statement of 
Ethical Conduct in Human Research.42 Ethics approvals 
have been obtained from the Human Research Ethics 
Committee of University of South Australia (ID: 
0000036440) and University of Tasmania (ID: H0017022). 
The study protocol and related documents have been 
submitted, reviewed and approved by the ethics commit-
tees before the study initiated. During the study, any 
amendment to the study protocol or related documents 
will be submitted to the ethics committees for approval 
prior to implementation.
The study is registered with the Australian and New 
Zealand Trials Registry. Online supplementary additional 
file 1 lists the WHO trial registration data set for the 
ReMInDAR trial. Online supplementary additional file 2 
lists the Standard Protocol Items: Recommendations for 
Interventional Trials.
A copy of the final report will be provided to the Austra-
lian Government Department of Health. All participating 
residential aged- care facilities, GPs and pharmacists may 
be provided with a summary of key findings. Participants 
and family members will be given a layperson summary if 
they wish to know the study results.
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